Summary
This Form 8-K filing from Alnylam Pharmaceuticals, Inc. (ALNY) on December 9, 2010, primarily reports a change in its Board of Directors. Specifically, Marsha H. Fanucci was elected as a Class II director, with her term set to expire at the 2012 annual meeting of stockholders. This appointment is a standard governance update. Investors should note that Ms. Fanucci received a stock option grant for 30,000 shares, vesting over three years, and will be compensated according to the company's established policy for non-employee directors. The filing does not disclose any significant operational, financial, or strategic changes, focusing instead on this directorial appointment.
Key Highlights
- 1Marsha H. Fanucci appointed as a Class II director on December 8, 2010.
- 2Ms. Fanucci's term as director will expire at the 2012 annual meeting of stockholders.
- 3Received a stock option grant for 30,000 shares of common stock.
- 4Stock option grant vests annually over a three-year period.
- 5Compensation for Ms. Fanucci as a director will follow the company's existing policy for non-employee directors.
- 6This filing is a routine corporate governance update and does not contain new financial or operational disclosures.
Frequently Asked Questions
Marsha H. Fanucci was elected as a Class II director to Alnylam Pharmaceuticals' Board of Directors on December 8, 2010. The filing does not provide specific details about her background or the reasons for her appointment, beyond it being a standard board addition.
Ms. Fanucci received a stock option grant for 30,000 shares of Alnylam's common stock. These options will vest annually over three years. Her additional compensation as a director will be in line with the company's established policy for non-employee directors, as described in their 2010 Proxy Statement.
No, this 8-K filing is solely focused on a change in the Board of Directors. It does not contain any information related to the company's financial results, operational updates, or strategic initiatives.